비낭포성 섬유증 기관지확장증 시장 : 세계 시장 규모, 점유율, 동향 분석, 기회, 예측 보고서(2019-2029년)

Non-cystic Fibrosis Bronchiectasis Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Treatment ; By Type ; By Diagnosis ; By End User ; By Region

US $ 4,850 ￦ 6,767,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,750 ￦ 8,023,000

Unprintable PDF (Group License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,372,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. Excel 파일이 제공됩니다.

한글목차

비낭포성 섬유증 기관지확장증 세계 시장 규모는 2029년까지 13억 달러에 달할 전망

세계 비낭포성 섬유증 기관지확장증 시장은 비낭포성 섬유증 기관지확장증 유병률 증가, 세계 인구의 급속한 고령화 및 호흡기 질환에 대한 감수성 증가, 진단 기술의 지속적인 발전, 인식 개선 및 조기 진단 노력으로 인해 호황을 누리고 있습니다.

전략 컨설팅 및 시장 조사 전문 기업 BlueWeave Consulting은 최근 연구에서 2022년 비낭포성 섬유증 기관지확장증 세계 시장 규모를 9억 4,000만 달러로 추산했습니다. 2023년부터 2029년까지 예측 기간 동안 세계 비낭포성 섬유증 기관지확장증 시장 규모는 연평균 5.55% 성장하여 2029년에는 12억 9,800만 달러에 달할 것으로 예측했습니다. 세계 비낭포성 섬유증 기관지확장증 시장의 주요 성장 촉진요인으로는 만성 질환의 유병률 증가, 의료비 지출 증가, 정부 이니셔티브 증가 등이 있습니다. 치료 옵션의 발전과 기관지확장증 증상에 대한 일반인 및 의료 전문가의 인식이 높아지면서 조기 진단 및 환자 관리가 개선되고 있습니다. 또한, 시장 성장은 특히 신흥 경제권에서 의료비 지출이 증가함에 따라 기관지확장증 환자의 진단 및 치료 접근성이 향상되면서 시장 성장에 큰 영향을 미치고 있습니다. 활발한 R&D 활동과 신흥국 시장이 제공하는 잠재적 기회는 예측 기간 동안 시장 개척을 더욱 촉진할 것으로 예상됩니다. 그러나 제한된 치료 옵션과 질환별 치료법의 부족, 질병 관리 및 환자 순응도 문제, 높은 치료비 및 의료비 부담은 분석 기간 동안 전체 시장 성장을 억제할 것으로 예상됩니다.

이 보고서는 세계 비낭포성 섬유증 기관지확장증 시장의 성장 잠재력, 향후 동향 및 통계에 대한 정보를 제공합니다. 또한 전체 시장 규모 예측을 촉진하는 요인도 다루고 있습니다. 이 보고서는 세계 비낭포성 섬유증 기관지확장증 시장의 최근 기술 동향과 의사결정자가 건전한 전략적 의사결정을 내릴 수 있는 업계 인사이트를 제공하기 위해 노력하고 있습니다. 또한, 시장 성장 촉진요인, 과제, 경쟁력에 대해서도 분석합니다.

목차

제1장 조사 체계

제2장 주요 요약

제3장 세계의 비낭포성 섬유증 기관지확장증 시장에 관한 인사이트

• 업계의 밸류체인 분석
• DROC 분석
  • 성장 원동력
    • 비낭포성 섬유증 기관지확장증 유병률 증가
    • 인구 고령화와 호흡기질환에 대한 높은 이환율
    • 진단 기술 진보
    • 의식 향상과 조기 진단에 대한 대처
  • 성장 억제요인
    • 한정된 치료 선택사항과 질환 특이적 치료법 결여
    • 질병 관리와 환자 순응도의 과제
    • 고액의 치료비와 헬스케어 부담
  • 기회
    • 맞춤형 의료와 정밀한 치료 접근법에 대한 수요 증가
    • 헬스케어비 증가와 인프라 개발
  • 과제
    • 복잡한 질환 병태생리학과 불균일성
    • 임상 관리 가이드라인에 관한 합의 결여
• 기술 진보/최근의 개발
• 규제 체계
• Porter's Five Forces 분석

제4장 세계의 비낭포성 섬유증 기관지확장증 시장 개요

• 시장 규모와 금액별 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 치료별
    • 수술
    • 물리치료
    • 예방 접종
    • 기도 약물요법
    • 항생제
    • 기타
  • 유형별
    • 정맥내
    • 어랄
    • 기타
  • 진단별
    • CT 스캔
    • 기관지경 검사
    • 흉부 X선
    • 폐기능
    • 객담 배양 검사
    • 혈액 검사
    • 기타
  • 최종사용자별
    • 진료소
    • 병원
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양(APAC)
    • 라틴아메리카(LATAM)
    • 중동 및 아프리카(MEA)

제5장 북미의 비낭포성 섬유증 기관지확장증 시장

• 시장 규모와 금액별 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 치료별
  • 유형별
  • 진단별
  • 최종사용자별
  • 국가별
    • 미국
    • 캐나다

제6장 유럽의 비낭포성 섬유증 기관지확장증 시장

• 시장 규모와 금액별 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 치료별
  • 유형별
  • 진단별
  • 최종사용자별
  • 국가별
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인
    • 네덜란드
    • 기타 유럽

제7장 아시아태평양의 비낭포성 섬유증 기관지확장증 시장

• 시장 규모와 금액별 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 치료별
  • 유형별
  • 진단별
  • 최종사용자별
  • 국가별
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주와 뉴질랜드
    • 인도네시아
    • 말레이시아
    • 싱가포르
    • 필리핀
    • 베트남
    • 기타 APAC

제8장 라틴아메리카의 비낭포성 섬유증 기관지확장증 시장

• 시장 규모와 금액별 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 치료별
  • 유형별
  • 진단별
  • 최종사용자별
  • 국가별
    • 브라질
    • 멕시코
    • 아르헨티나
    • 페루
    • 콜롬비아
    • 기타 중남미

제9장 중동 및 아프리카의 비낭포성 섬유증 기관지확장증 시장

• 시장 규모와 금액별 예측, 2019-2029년
  • 금액별
• 시장 점유율과 예측
  • 치료별
  • 유형별
  • 진단별
  • 최종사용자별
  • 국가별
    • 사우디아라비아
    • 아랍에미리트
    • 카타르
    • 쿠웨이트
    • 남아프리카공화국
    • 나이지리아
    • 알제리
    • 기타 MEA

제10장 경쟁 상황

• 주요 기업과 그 제품 리스트
• 세계의 비낭포성 섬유증 기관지확장증 기업의 시장 점유율 분석, 2022년
• 경영 파라미터에 의한 경쟁 벤치마킹
• 주요 전략적 개발(합병, 인수, 파트너십 등)

제11장 세계의 비낭포성 섬유증 기관지확장증 시장에 대한 COVID-19의 영향

제12장 기업 개요(기업 개요, 재무 매트릭스, 경쟁 상황, 주요 인재, 주요 경쟁, 연락처 주소, 전략적 전망 및 SWOT 분석)

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Pfizer Inc.
• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Sunovion Pharmaceuticals Inc.
• Insmed Incorporated
• Bayer AG
• Other Prominent Players

제13장 주요 전략적 추천사항

제14장 조사 방법

ksm

영문 목차

영문목차

Global Non-cystic Fibrosis Bronchiectasis Market Size Set to Touch USD 1.3 Billion by 2029.

Global non-cystic fibrosis bronchiectasis market is flourishing because of the rising prevalence of non-cystic fibrosis bronchiectasis, rapidly aging world population and its higher susceptibility to respiratory diseases, ongoing advancements in diagnostic technologies, and growing awareness and early diagnosis initiatives.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global non-cystic fibrosis bronchiectasis market size at USD 0.94 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global non-cystic fibrosis bronchiectasis market size to grow at a CAGR of 5.55% reaching a value of USD 1.298 billion by 2029. Major growth drivers for the global non-cystic fibrosis bronchiectasis market include an increasing prevalence of chronic diseases, coupled with a rising healthcare expenditure and growing government initiatives. Advancements in treatment options and growing awareness among the general population and healthcare professionals about bronchiectasis symptoms have led to early diagnosis and improved patient management. Also, the market's growth is notably influenced by rising healthcare spending, particularly in emerging economies, which has facilitated better access to diagnosis and treatment for bronchiectasis patients. The rise in research and development activities and the potential opportunities presented by emerging markets are expected to further propel the market's development during the forecast period. However, limited treatment options and lack of disease-specific therapies, challenges in disease management and patient adherence, and the high cost of treatment and healthcare burden are anticipated to restrain the overall market growth during the period in analysis.

Global Non-cystic Fibrosis Bronchiectasis Market - Overview:

The global non-cystic fibrosis bronchiectasis market refers to the worldwide industry involved in the diagnosis, treatment, and management of non-cystic fibrosis bronchiectasis, a chronic respiratory condition. Bronchiectasis is characterized by permanent dilation of the bronchi, leading to recurrent respiratory infections and impaired lung function. Unlike cystic fibrosis-related bronchiectasis, non-cystic fibrosis bronchiectasis is not caused by the genetic disorder cystic fibrosis. The market encompasses various healthcare stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions, all contributing to the development of innovative therapies, medications, and diagnostic tools to address the challenges posed by non-cystic fibrosis bronchiectasis and improve patients' quality of life.

Impact of COVID-19 on Global Non-cystic Fibrosis Bronchiectasis Market:

COVID-19 pandemic adversely affected the global non-cystic fibrosis bronchiectasis market. During the pandemic, healthcare systems were overwhelmed with managing COVID-19 patients, leading to a reduced focus on non-emergency conditions like bronchiectasis. Patients with respiratory conditions faced challenges in accessing healthcare facilities and adhering to treatment regimens due to restrictions and safety concerns. Also, disruptions in the supply chain and clinical trials affected the availability of treatments and research activities. However, with the gradual containment of the pandemic, the market is expected to recover as healthcare systems restore non-emergency services, and efforts to improve respiratory care continue.

Global Non-cystic Fibrosis Bronchiectasis Market - By End User:

On the basis of end user, the global non-cystic fibrosis bronchiectasis market is bifurcated into Clinic and Hospital segments. The hospital segment held a higher market share by end-users. Hospitals are major healthcare centers where patients with respiratory conditions like non-cystic fibrosis bronchiectasis often seek diagnosis, treatment, and management. Hospitals typically have advanced medical facilities, equipment, and specialized healthcare professionals, making them capable of providing comprehensive care for bronchiectasis patients. Also, non-cystic fibrosis bronchiectasis may require specialized diagnostic tests and treatments, such as CT scans, bronchoscopies, and lung function tests, which are readily available in hospitals. The hospital setting also allows for closer monitoring of patients and immediate intervention in case of complications.

Competitive Landscape:

Major players operating in the global non-cystic fibrosis bronchiectasis market include: Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals Inc., Insmed Incorporated, and Bayer AG. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-cystic Fibrosis Bronchiectasis Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Non-cystic Fibrosis Bronchiectasis Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Non-cystic Fibrosis Bronchiectasis Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing Prevalence of Non-Cystic Fibrosis Bronchiectasis
    • 3.2.1.2. Aging Population and Higher Susceptibility to Respiratory Diseases
    • 3.2.1.3. Advancements in Diagnostic Technologies
    • 3.2.1.4. Growing Awareness and Early Diagnosis Initiatives
  • 3.2.2. Restraints
    • 3.2.2.1. Limited Treatment Options and Lack of Disease-Specific Therapies
    • 3.2.2.2. Challenges in Disease Management and Patient Adherence
    • 3.2.2.3. High Cost of Treatment and Healthcare Burden
  • 3.2.3. Opportunities
    • 3.2.3.1. Rising Demand for Personalized Medicine and Precision Treatment Approaches
    • 3.2.3.2. Increasing Healthcare Expenditure and Infrastructure Development
  • 3.2.4. Challenges
    • 3.2.4.1. Complex Disease Pathophysiology and Heterogeneity
    • 3.2.4.2. Lack of Consensus on Clinical Management Guidelines
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Non-cystic Fibrosis Bronchiectasis Market Overview

• 4.1. Market Size & Forecast by Value, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment
    • 4.2.1.1. Surgery
    • 4.2.1.2. Physiotherapy
    • 4.2.1.3. Vaccination
    • 4.2.1.4. Airway Pharmacotherapy
    • 4.2.1.5. Antibiotics
    • 4.2.1.6. Others
  • 4.2.2. By Type
    • 4.2.2.1. Intravenous
    • 4.2.2.2. Oral
    • 4.2.2.3. Others
  • 4.2.3. By Diagnosis
    • 4.2.3.1. CT scan
    • 4.2.3.2. Bronchoscopy
    • 4.2.3.3. Chest X-Ray
    • 4.2.3.4. Lung Function
    • 4.2.3.5. Sputum Culture Test
    • 4.2.3.6. Blood Tests
    • 4.2.3.7. Others
  • 4.2.4. By End User
    • 4.2.4.1. Clinic
    • 4.2.4.2. Hospital
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia Pacific (APAC)
    • 4.2.5.4. Latin America (LATAM)
    • 4.2.5.5. Middle East and Africa (MEA)

5. North America Non-cystic Fibrosis Bronchiectasis Market

• 5.1. Market Size & Forecast by Value, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Type
  • 5.2.3. By Diagnosis
  • 5.2.4. By End User
  • 5.2.5. By Country
    • 5.2.5.1. United States
    • 5.2.5.1.1. By Treatment
    • 5.2.5.1.2. By Type
    • 5.2.5.1.3. By Diagnosis
    • 5.2.5.1.4. By End User
    • 5.2.5.2. Canada
    • 5.2.5.2.1. By Treatment
    • 5.2.5.2.2. By Type
    • 5.2.5.2.3. By Diagnosis
    • 5.2.5.2.4. By End User

6. Europe Non-cystic Fibrosis Bronchiectasis Market

• 6.1. Market Size & Forecast by Value, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Type
  • 6.2.3. By Diagnosis
  • 6.2.4. By End User
  • 6.2.5. By Country
    • 6.2.5.1. Germany
    • 6.2.5.1.1. By Treatment
    • 6.2.5.1.2. By Type
    • 6.2.5.1.3. By Diagnosis
    • 6.2.5.1.4. By End User
    • 6.2.5.2. United Kingdom
    • 6.2.5.2.1. By Treatment
    • 6.2.5.2.2. By Type
    • 6.2.5.2.3. By Diagnosis
    • 6.2.5.2.4. By End User
    • 6.2.5.3. Italy
    • 6.2.5.3.1. By Treatment
    • 6.2.5.3.2. By Type
    • 6.2.5.3.3. By Diagnosis
    • 6.2.5.3.4. By End User
    • 6.2.5.4. France
    • 6.2.5.4.1. By Treatment
    • 6.2.5.4.2. By Type
    • 6.2.5.4.3. By Diagnosis
    • 6.2.5.4.4. By End User
    • 6.2.5.5. Spain
    • 6.2.5.5.1. By Treatment
    • 6.2.5.5.2. By Type
    • 6.2.5.5.3. By Diagnosis
    • 6.2.5.5.4. By End User
    • 6.2.5.6. The Netherlands
    • 6.2.5.6.1. By Treatment
    • 6.2.5.6.2. By Type
    • 6.2.5.6.3. By Diagnosis
    • 6.2.5.6.4. By End User
    • 6.2.5.7. Rest of Europe
    • 6.2.5.7.1. By Treatment
    • 6.2.5.7.2. By Type
    • 6.2.5.7.3. By Diagnosis
    • 6.2.5.7.4. By End User

7. Asia-Pacific Non-cystic Fibrosis Bronchiectasis Market

• 7.1. Market Size & Forecast by Value, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Type
  • 7.2.3. By Diagnosis
  • 7.2.4. By End User
  • 7.2.5. By Country
    • 7.2.5.1. China
    • 7.2.5.1.1. By Treatment
    • 7.2.5.1.2. By Type
    • 7.2.5.1.3. By Diagnosis
    • 7.2.5.1.4. By End User
    • 7.2.5.2. India
    • 7.2.5.2.1. By Treatment
    • 7.2.5.2.2. By Type
    • 7.2.5.2.3. By Diagnosis
    • 7.2.5.2.4. By End User
    • 7.2.5.3. Japan
    • 7.2.5.3.1. By Treatment
    • 7.2.5.3.2. By Type
    • 7.2.5.3.3. By Diagnosis
    • 7.2.5.3.4. By End User
    • 7.2.5.4. South Korea
    • 7.2.5.4.1. By Treatment
    • 7.2.5.4.2. By Type
    • 7.2.5.4.3. By Diagnosis
    • 7.2.5.4.4. By End User
    • 7.2.5.5. Australia & New Zealand
    • 7.2.5.5.1. By Treatment
    • 7.2.5.5.2. By Type
    • 7.2.5.5.3. By Diagnosis
    • 7.2.5.5.4. By End User
    • 7.2.5.6. Indonesia
    • 7.2.5.6.1. By Treatment
    • 7.2.5.6.2. By Type
    • 7.2.5.6.3. By Diagnosis
    • 7.2.5.6.4. By End User
    • 7.2.5.7. Malaysia
    • 7.2.5.7.1. By Treatment
    • 7.2.5.7.2. By Type
    • 7.2.5.7.3. By Diagnosis
    • 7.2.5.7.4. By End User
    • 7.2.5.8. Singapore
    • 7.2.5.8.1. By Treatment
    • 7.2.5.8.2. By Type
    • 7.2.5.8.3. By Diagnosis
    • 7.2.5.8.4. By End User
    • 7.2.5.9. Philippines
    • 7.2.5.9.1. By Treatment
    • 7.2.5.9.2. By Type
    • 7.2.5.9.3. By Diagnosis
    • 7.2.5.9.4. By End User
    • 7.2.5.10. Vietnam
    • 7.2.5.10.1. By Treatment
    • 7.2.5.10.2. By Type
    • 7.2.5.10.3. By Diagnosis
    • 7.2.5.10.4. By End User
    • 7.2.5.11. Rest of APAC
    • 7.2.5.11.1. By Treatment
    • 7.2.5.11.2. By Type
    • 7.2.5.11.3. By Diagnosis
    • 7.2.5.11.4. By End User

8. Latin America Non-cystic Fibrosis Bronchiectasis Market

• 8.1. Market Size & Forecast by Value, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Type
  • 8.2.3. By Diagnosis
  • 8.2.4. By End User
  • 8.2.5. By Country
    • 8.2.5.1. Brazil
    • 8.2.5.1.1. By Treatment
    • 8.2.5.1.2. By Type
    • 8.2.5.1.3. By Diagnosis
    • 8.2.5.1.4. By End User
    • 8.2.5.2. Mexico
    • 8.2.5.2.1. By Treatment
    • 8.2.5.2.2. By Type
    • 8.2.5.2.3. By Diagnosis
    • 8.2.5.2.4. By End User
    • 8.2.5.3. Argentina
    • 8.2.5.3.1. By Treatment
    • 8.2.5.3.2. By Type
    • 8.2.5.3.3. By Diagnosis
    • 8.2.5.3.4. By End User
    • 8.2.5.4. Peru
    • 8.2.5.4.1. By Treatment
    • 8.2.5.4.2. By Type
    • 8.2.5.4.3. By Diagnosis
    • 8.2.5.4.4. By End User
    • 8.2.5.4.5.
    • 8.2.5.5. Colombia
    • 8.2.5.5.1. By Treatment
    • 8.2.5.5.2. By Type
    • 8.2.5.5.3. By Diagnosis
    • 8.2.5.5.4. By End User
    • 8.2.5.6. Rest of LATAM
    • 8.2.5.6.1. By Treatment
    • 8.2.5.6.2. By Type
    • 8.2.5.6.3. By Diagnosis
    • 8.2.5.6.4. By End User

9. Middle East & Africa Non-cystic Fibrosis Bronchiectasis Market

• 9.1. Market Size & Forecast by Value, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Type
  • 9.2.3. By Diagnosis
  • 9.2.4. By End User
  • 9.2.5. By Country
    • 9.2.5.1. Saudi Arabia
    • 9.2.5.1.1. By Treatment
    • 9.2.5.1.2. By Type
    • 9.2.5.1.3. By Diagnosis
    • 9.2.5.1.4. By End User
    • 9.2.5.2. UAE
    • 9.2.5.2.1. By Treatment
    • 9.2.5.2.2. By Type
    • 9.2.5.2.3. By Diagnosis
    • 9.2.5.2.4. By End User
    • 9.2.5.3. Qatar
    • 9.2.5.3.1. By Treatment
    • 9.2.5.3.2. By Type
    • 9.2.5.3.3. By Diagnosis
    • 9.2.5.3.4. By End User
    • 9.2.5.4. Kuwait
    • 9.2.5.4.1. By Treatment
    • 9.2.5.4.2. By Type
    • 9.2.5.4.3. By Diagnosis
    • 9.2.5.4.4. By End User
    • 9.2.5.5. South Africa
    • 9.2.5.5.1. By Treatment
    • 9.2.5.5.2. By Type
    • 9.2.5.5.3. By Diagnosis
    • 9.2.5.5.4. By End User
    • 9.2.5.6. Nigeria
    • 9.2.5.6.1. By Treatment
    • 9.2.5.6.2. By Type
    • 9.2.5.6.3. By Diagnosis
    • 9.2.5.6.4. By End User
    • 9.2.5.7. Algeria
    • 9.2.5.7.1. By Treatment
    • 9.2.5.7.2. By Type
    • 9.2.5.7.3. By Diagnosis
    • 9.2.5.7.4. By End User
    • 9.2.5.8. Rest of MEA
    • 9.2.5.8.1. By Treatment
    • 9.2.5.8.2. By Type
    • 9.2.5.8.3. By Diagnosis
    • 9.2.5.8.4. By End User

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Non-cystic Fibrosis Bronchiectasis Company Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Non-cystic Fibrosis Bronchiectasis Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

• 12.1. Novartis AG
• 12.2. Teva Pharmaceutical Industries Ltd.
• 12.3. Mylan N.V.
• 12.4. Pfizer Inc.
• 12.5. GlaxoSmithKline plc
• 12.6. AstraZeneca plc
• 12.7. Boehringer Ingelheim GmbH
• 12.8. Sunovion Pharmaceuticals Inc.
• 12.9. Insmed Incorporated
• 12.10. Bayer AG
• 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumption & Limitation

관련자료